UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-31275

Vertical Health Solutions, Inc.

(Exact name of registrant as specified in its charter)


Florida		59-3635262
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

7760 France Ave South, 11th Floor Minneapolis, MN		55435
(Address of principal executive offices)		(Zip Code)

(612) 568-4210

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Exchange Act: Common Stock

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer	¨	Accelerated Filer	¨

Non-accelerated Filer	¨	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ¨ NO x

There were 13,978,146 shares of the registrant’s common stock par value $0.001 per share outstanding as of August 14, 2013.

TABLE OF CONTENTS

		Page
PART I:	FINANCIAL INFORMATION
Item 1	Financial Statements (unaudited):
	Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012		3
	Consolidated Statements of Operations for the Three and Six Months Ended June
	30, 2013 and 2012 and the period from inception (February 1, 2009) to June 30, 2013		4
	Consolidated Statements of Cash Flows for the Six Months Ended June
	31, 2013 and 2012 and the period from inception (February 1, 2009) to June 30, 2013		5
	Notes to Consolidated Financial Statements		7
Item 2	Management’s Discussion and Analysis of Financial Condition
	and Results of Operations		18
Item 3	Quantitative and Qualitative Disclosures About Market Risk		23
Item 4	Controls and Procedures		23

PART II:	OTHER INFORMATION
Item 1	Legal Proceedings		23
Item 1A	Risk Factors		23
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds		30
Item 3	Defaults Upon Senior Securities		30
Item 4	Mine Safety Disclosures		30
Item 5	Other Information		30
Item 6	Exhibits		31
	Signatures		32

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

VERTICAL HEALTH SOLUTIONS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED BALANCE SHEETS

	June 30,			December 31,
	2013			2012
	(unaudited)			(audited)
ASSETS
Current assets:
Cash	$	64,609		$	550,403
Accounts receivable		6,726			9,408
Prepaid expenses and other current assets		10,259			24,533
Total current assets		81,594			584,344

Property and equipment, net		6,545			2,826
Software development costs, net		239,171			275,967
Deferred financing costs, net		633,912			625,838

Total assets	$	961,222		$	1,488,975

LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	106,770		$	156,709
Short-term convertible notes payable, net of discounts ($116,948
and $16,948 face value at June 30, 2013 and December 31, 2012)		23,892			16,948
Accrued interest payable		8,587			16,799
Accrued payroll and benefits		9,860			71,732
Accrued royalties-related party		200,000			150,000
Deferred revenue		31,661			29,320
Current maturities of long-term convertible debt, net of discounts
($406,000 face value at June 30, 2013 and December 31, 2012)		331,812			73,581
Total current liabilities		712,582			515,089

Long-term accrued interest payable		60,582			—
Long-term convertible debt, net of current maturities and discounts		350,129			92,212
Total long-term liabilities		410,771			92,212

Total liabilities		1,123,293			607,301

Stockholders' equity (deficit):
Common stock, $0.001 par value, 250,000,000 shares
authorized; 13,978,146 and 13,473,299 issued and outstanding
at June 30, 2013 and December 31, 2012, respectively		13,978			13,473
Additional paid in capital		10,782,432			9,735,455
Deficit accumulated during the development stage		(10,958,481	)		(8,867,254	)

Total stockholders' equity (deficit)		(162,071	)		881,674

Total liabilities and stockholders' equity (deficit)	$	961,222		$	1,488,975

See accompanying notes to the consolidated financial statements.

VERTICAL HEALTH SOLUTIONS, INC.
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

		Three Months Ended June 30, 2013			Three Months Ended June 30, 2012			Six Months Ended June 30, 2013			Six Months Ended June 30, 2012			Period from Inception (February 1, 2009) to June 30, 2013

Revenues	$	16,083		$	53,666		$	29,446		$	65,539		$	105,629
Costs of revenues		65,775			71,378			134,212			91,578			422,459
Gross loss		(49,692	)		(17,712	)		(104,766	)		(26,039	)		(316,830	)

Operating expenses:
Research and development		75,324			27,095			182,105			131,911			880,178
Selling, general and administrative		369,322			412,359			852,857			799,351			5,392,083
Investor relations expense		—			—			—			—			819,118
Merger related costs		—			—			—			—			347,312

Total operating expenses		444,646			439,454			1,034,962			931,262			7,438,691

Loss from operations		(494,338	)		(457,166	)		(1,139,728	)		(957,301	)		(7,755,521	)

Other income (expense):
Interest income		—			4			—			7			674
Interest expense		(544,166	)		(182,237	)		(951,499	)		(314,752	)		(2,243,737	)
Beneficial conversion expense		—			—			—			—			(809,533	)
Loss on debt extinguishment		—			—			—			—			(171,548	)
Gain on fair value adjustment
of warrant derivative liability		—			1,129			—			1,129			203

Total other income (expense)		(544,166	)		(181,104	)		(951,499	)		(313,616	)		(3,223,941	)

Net loss before income taxes		(1,038,504	)		(638,270	)		(2,091,227	)		(1,270,917	)		(10,979,462	)

Income tax benefit		—			18,900			—			18,900			20,981

Net loss and comprehensive loss	$	(1,038,504	)	$	(619,370	)	$	(2,091,227	)	$	(1,252,017	)	$	(10,958,481	)

Net loss per common share -
basic and diluted	$	(0.07	)	$	(0.06	)	$	(0.15	)	$	(0.12	)

Weighted average common shares
outstanding - basic		13,877,927			10,837,999			13,708,775			10,767,247

Weighted average common shares
outstanding - diluted		13,877,927			10,837,999			13,708,775			10,767,247

See accompanying notes to the consolidated financial statements.

VERTICAL HEALTH SOLUTIONS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Six Months Ended Ju			Six Months Ended			Period from Inception (February 1, 2009) to
	June 30, 2013			June 30, 2012			June 30, 2013

Cash flows used in operating activities:
Net loss	$	(2,091,227	)	$	(1,252,017	)	$	(10,958,481	)
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation and amortization of assets		274,647			86,686			915,955
Amortization of debt discount		648,092			108,989			1,194,805
Stock-based compensation		197,505			172,606			2,146,779
Non-cash merger related costs		—			—			42,828
Interest expense for warrant liability derivative
recorded in excess of discounted debt		—			133,966			133,966
Beneficial conversion expense		—			—			809,533
Loss on debt extinguishment		—			—			171,548
Gain on fair value adjustment of warrant derivative
liability		—			(1,129	)		(203	)
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable		2,682			(52,112	)		(6,726	)
(Increase) decrease in prepaid expenses and
other current assets		14,274			3,598			(10,259	)
Increase (decrease) in accounts payable		(49,939	)		(14,525	)		57,082
Increase in accrued interest		53,582			39,483			201,520
Increase (decrease) in accrued payroll and
benefits		(61,872	)		(2,093	)		3,263
Increase in accrued royalties-related party		50,000			50,000			200,000
Increase in deferred revenue		2,341			9,558			31,661
Increase in accrued other expenses		—			14,400			—
Increase (decrease) in accounts payable-related
parties		—			—			966,294

Net cash used in operating activities		(959,915	)		(702,590	)		(4,100,435	)

Cash flows provided by (used in) investing activities:
Decrease in restricted cash		—			25,299			—
Capitalized software development costs		—			—			(367,956	)
Purchase of property and equipment		(6,829	)		—			(19,279	)
Cash received from VHS merger		—			—			1,145
Net cash provided by (used in) investing
activities		(6,829	)		25,299			(386,090	)


Cash flows provided by financing activities:
Proceeds from issuance of short-term convertible debt		100,000			—			100,000
Proceeds from issuance of long-term convertible debt		437,500			406,000			3,584,000
Debt financing costs		(56,550	)		(46,709	)		(445,244	)
Proceeds from issuance of promissory notes		—			—			265,000
Proceeds from exercise of stock warrants		—			—			6,714
Proceeds from sale of common stock and warrants,
net of issuance costs		—			180,150			1,040,664

Net cash provided by financing activities		480,950			539,441			4,551,134

Increase (decrease) in cash		(485,794	)		(137,850	)		64,609

Cash:
Beginning of period		550,403			168,780			—

End of period	$	64,609		$	30,930		$	64,609

Supplemental disclosure of cash flow information:
Cash paid for interest	$	8,009		$	—		$	31,931

Non-cash investing and financing activities:

Accounts payable - related parties incurred for the
purchase of intangible assets	$	—		$	—		$	100,000
Accounts payable - related party reduced by
forgiveness of debt and issuance of
common stock	$	—		$	—		$	1,066,294
Increase in deferred debt financing costs by
issuing stock warrants	$	186,265		$	—		$	833,844
Accrued interest converted to common stock	$	1,212		$	39,189		$	132,351
Debt converted to common stock	$	125,000		$	32,500		$	1,787,500
Increase in accounts payable, accrued expenses and
short-term convertible debt for liabilities assumed
in reverse merger	$	—		$	—		$	43,973
Increase in debt discounts on long-term promissory
notes by issuing stock warrants	$	—		$	—		$	157,128
Increase in debt discounts on convertible
notes by issuing stock warrants	$	272,523		$	—		$	1,081,965
Increase in debt discounts on long-term convertible
notes by issuing warrant liability derivatives	$	—		$	406,000		$	406,000
Increase in accounts payable for deferred financing
costs	$	—		$	—		$	29,260
Increase in accounts payable for stock issuance costs		—		$	16,488		$	—
Warrant derivative liability reclassified to equity	$	—		$	406,118		$	539,763
Increase in debt discounts in connection with
beneficial conversion feature on
convertible notes	$	264,977		$	—		$	1,184,535

See accompanying notes to the consolidated financial statements.

VERTICAL HEALTH SOLUTIONS, INC.

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED STATEMENTS

(UNAUDITED)

1. BASIS OF PRESENTATION

The accompanying unaudited financial statements of Vertical Health Solutions, Inc. (“VHS” or the “Company”) have been prepared in accordance with United States generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. These statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2012.

The accompanying financial statements include the accounts of the Company and include the acquisition of its wholly-owned subsidiary OnPoint Medical Diagnostics, Inc. (“OnPoint”) which was completed through a reverse merger on April 15, 2011. Intercompany transactions and balances are eliminated in consolidation.

The on-going operations of the Company are that of OnPoint. OnPoint provides a software-as-a-service (SAAS) enterprise quality assurance solution for the diagnostics imaging market. OnPoint has not yet generated significant revenue and is considered a development stage company as of June 30, 2013.

In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.

Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December 31, 2012, we incurred a net loss of $4,595,984. For the six months ended June 30, 2013, we incurred a net loss of $2,091,227. At June 30, 2013, we have cash of $64,609, an accumulated deficit of $10,958,481 and negative working capital of $630,988. Our ability to continue as a going concern is dependent on our ability to raise the required additional capital or debt financing to meet short and long-term operating requirements. During the first six months of 2013, we issued convertible debt of $537,500. These funds are expected to last us through September 2013 at which time future private placements of equity capital or debt financing will be needed to fund our long-term operating requirements. If we raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our current stockholders could be reduced, and such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective business endeavors or opportunities, which could significantly and materially restrict our operations. We are continuing to pursue external financing alternatives to improve our working capital position. If we are unable to obtain the necessary capital, we may have to reduce our expenses or cease operations. These conditions, as well as the general financial condition of the Company raise substantial doubt as to the Company’s ability to continue as a going concern.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND OTHER INFORMATION

Use of Estimates

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.

Accounts Receivable and Allowance for Doubtful Accounts

The Company evaluates the collectability of accounts receivable based on a combination of factors. In circumstances where the Company is aware of a specific customer’s inability to meet its financial obligations, a specific reserve is recorded to reduce the receivable to the amount the Company believes will be collected. For all other customers, the Company records an allowance for doubtful accounts based on the length of time the receivables are past due and historical experience. Typically, the Company considers all receivables not paid within specified terms of the invoice as past due. The Company does not accrue interest on past due receivables.

As of June 30, 2013 and December 31, 2012, management has deemed all accounts receivable to be fully collectible and has not recorded a reserve for doubtful accounts. If circumstances change, the Company’s estimates of the collectability of amounts due could be reduced and such reductions could be material.

Software Development Costs

The Company applies ASC 350-40, Intangibles - Goodwill and Other - Internal Use Software, in review of certain systems projects. These system projects relate to software we do not intend to sell as a license, but will be used in our hosted SaaS model. In this review, all costs incurred during the preliminary project stage are expensed as incurred which include research and development expenses. Once the project has been committed to and it is probable that the project will meet functional requirements, qualifying costs are capitalized. These capitalized software costs are amortized on a project-by-project basis over the expected economic life of the underlying product on a straight-line basis, which is typically two to six years. Amortization commences when the software is available for its intended use. During the three and six months ended June 30, 2013 and 2012, the Company did not capitalize any software development costs. The Company’s current software platform was available for customer use as of September 30, 2011 and is being amortized over a five year period.

Deferred Financing Costs

Deferred financing costs were incurred in connection with the Company’s issuance of convertible notes and promissory notes. Amortization of these costs is provided on the effective-interest method over the term of the related debt.

Minimum Royalty Payments

The Company’s policy is to recognize the minimum royalty payments due for the underlying technology embedded in the Company’s software based on the occurrence of the Company’s sales activity. If it is determined that the minimum obligation will not be met, an accrual will be recorded accordingly. During the three and six months ended June 30, 2013 and 2012, the Company determined that the minimum obligation would not be met through a percentage of our sales and therefore, during the three and six month periods ended June 30, 2013 and 2012, the Company accrued and expensed $25,000 and $37,500, and $50,000 and $50,000, respectively. Accrued royalties aggregated $200,000 and $150,000 at June 30, 2013 and December 31, 2012, respectively.

Revenue Recognition

The Company is a development stage company and has not generated significant revenue since inception (February 1, 2009) . Revenue under existing SaaS contracts is recorded as deferred revenue upon execution of a software subscription agreement and receipt of payment. Revenue is then recognized on a straight-line basis over the life of the subscription agreement, which is typically 12 to 36 months. In addition, software project revenue is recognized as services are performed. All customer contracts are reviewed for the existence of multiple element arrangements. If multiple elements were to exist, the value of the revenues associated with the customer contract would be allocated to each element, and recognized accordingly.

Stock-Based Compensation

The Company recognizes expense for its stock-based compensation based on the fair value of the awards granted. The fair value of stock options is estimated at the date of grant using the Black-Scholes option valuation model. The Company makes assumptions about complex and subjective variables and the related tax impact. These variables include, but are not limited to, the Company's stock price volatility and stock option exercise behaviors. The Company recognizes the compensation cost for stock-based awards on a straight-line basis over the requisite service period for the entire award.

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss for the period by the weighted-average number of shares outstanding during the period, increased by potentially dilutive common shares (“dilutive securities”) that were outstanding during the period. Dilutive securities include stock options and warrants granted and convertible notes.

For the three and six months ended June 30, 2013 and 2012, options, warrants, and conversion shares related to convertible notes were excluded from the calculation of the diluted net loss per share as their effect would have been anti-dilutive.

Income Taxes

The Company accounts for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the tax consequences of temporary differences between the tax basis of assets and liabilities and their carrying amounts for financial reporting purposes using enacted tax rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company accounts for income taxes pursuant to Financial Accounting Standards Board guidance specifically related to uncertain tax positions. This guidance presents a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company believes its income tax filing positions and deductions will be sustained upon examination and, accordingly, no accrual related to uncertain tax positions has been recorded at June 30, 2013 and December 31, 2012. In accordance with the guidance, the Company has adopted a policy under which, if required to be recognized in the future, interest related to the underpayment of income taxes will be classified as a component of interest expense and any related penalties will be classified in operating expenses. The Company’s remaining open tax years subject to examination include 2009, 2010, 2011 and 2012.

The Company has recorded a full valuation allowance against its deferred tax assets at June 30, 2013 and December 31, 2012.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash, accounts receivable, accounts payable, and debt. The Company is required to estimate the fair value of all financial instruments at the balance sheet date based on relevant market information. The Company considers the carrying values of its cash, accounts receivable and accounts payable to approximate fair values due to their short-term nature. At June 30, 2013 and December 31, 2012, it was deemed impracticable to estimate the fair value of the Company’s debt, as quoted market prices are not available, a valuation model necessary to estimate the fair value has not been developed, and the cost of obtaining an independent valuation is deemed excessive in relation to the value of debt held by the Company.

Debt Issued with Warrants

The Company accounts for the issuance of debt and related warrants by allocating the debt proceeds between the debt and warrants based on the relative estimated fair values of the debt security without regard for the warrants and the estimated fair value of the warrants themselves. The amount allocated to the warrants would then be reflected as both an increase to equity, and as a debt discount that would be amortized over the term of the debt. However, in circumstances where warrants must be accounted for as a liability, the full estimated fair value of the warrants is established as both a liability and a debt discount. In some cases, if the value of the warrants is greater than the principal amount received, an immediate interest expense charge is recorded for the excess.

In accounting for convertible debt instruments, the proceeds from issuance of the convertible notes are first allocated between the convertible notes and the warrants. If the amount allocated to convertible notes results in an effective per share conversion price less than the fair value of the Company’s common stock on the date of issuance, the intrinsic value of this beneficial conversion feature is recorded as a further discount to the convertible debt with a corresponding increase to additional paid in capital. The beneficial conversion feature discount is equal to the difference between the effective conversion price and the fair value of the Company’s common stock.

Comprehensive Income (Loss)

Comprehensive income (loss) includes net income (loss) and items defined as other comprehensive income (loss). Items defined as other comprehensive income (loss) include items such as foreign currency translation adjustments and unrealized gains and losses on certain marketable securities. For the three and six months ended June 30, 2013 and 2012, there were no adjustments to net loss to arrive at comprehensive loss.

Recent Accounting Pronouncements

There were no new accounting standards issued or effective during the three months ended June 30, 2013 that had or are expected to have a material impact on the Company’s results of operations, financial condition or cash flows.

Reclassifications

Certain items previously reported were reclassified for consistency with the current presentation. These reclassifications had no effect on net loss and comprehensive loss as previously reported.

3. RELATED PARTIES

At June 30, 2013 and December 31, 2012, the Company had $200,000 and $150,000, respectively of accrued royalties due to a related party (minority shareholder) which included the minimum royalty license fees for 2012 and 2011 that are due to the Mayo Foundation for Medical Education and Research and a portion of the 2013 minimum royalty license fee. The 2012 and 2011 fees of $150,000 were past due and unpaid at June 30, 2013. The Company has since negotiated revised payment terms with Mayo on the Company’s outstanding balance due for 2011 and 2012 royalty payments. Interest to be paid on the $150,000 outstanding balance related to 2011 and 2012 royalty payments is calculated based on Prime plus 2.00%, or 5.25% per annum. The revised payment terms require monthly payments beginning in August 2013 such that $150,000 of the balance due will be paid by December 31, 2013, and interest thereon to be paid by January 31, 2013.

At June 30, 2013 and December 31, 2012, accrued interest payable on outstanding debt held by board members was $5,318 and $0, respectively. Interest expense on the related party debt for the three and six months ended June 30, 2013 and 2012 was $3,099 and $5,318, and $13,213 and $26,425, respectively.

At June 30, 2013 and December 31, 2012, there were unpaid consulting fees of $10,465 and $19,500, respectively, which are due to the Company’s contract CFO. During the three and six months ended June 30, 2013, the Company incurred $10,465 and $37,180, respectively, in consulting fees from the Company’s contract CFO. During both of the three and six months ended June 30, 2012, the Company incurred consulting fees of $12,545.

4. CONVERTIBLE PROMISSORY NOTES

Short-term Convertible Debt

2011 Short-term Convertible Debt

At June 30, 2013 and December 31, 2012, the Company had $16,948 in convertible short-term notes which accrue interest at 0.21% per annum, and are due on demand. Principal and accrued interest is convertible into common stock using a conversion price of 80% of the fair value of the common stock.

2013 Short-term Convertible Debt Issuance (Tranche D)

In June 2013, the Company issued $100,000 in convertible notes in a private placement offering of convertible promissory notes to certain accredited investors. The notes accrue interest at 12% per annum and such interest is payable at maturity. Each note will mature on the six month anniversary of its issuance date and is junior to all other debt.

The convertible promissory notes may be converted at the option of the note holder into shares of the Company’s common stock at a conversion price of $0.125 per share. The debt principal and any accrued interest will automatically convert into shares of common stock at a conversion price of $0.125 per share, upon the earlier of the notes’ maturity or a change of control of the Company. Also, if the Company sells an aggregate of $2,000,000 of common stock, the principal and interest will automatically convert into common stock at a price equal to the lesser of the price per share paid by the investors purchasing such stock at such first closing or $0.125 per share. This feature has been determined to not meet the criteria for being a derivative.

In connection with the note issuances, the Company granted each note holder warrants to purchase a number of shares of common stock equal to the advance amount (100,000 in total). The warrants have an exercise price of $0.50 per share and have a 10 year term from their respective note issuance date. Upon issuance, the relative fair value of the 100,000 warrants related to the $100,000 in convertible debt was estimated to be $45,489. The relative fair value was determined utilizing a Black-Scholes pricing model. A beneficial conversion feature of $54,511 resulted from a conversion price of $0.125 while the estimated fair value of the common stock was $0.83 per share. Both the value assigned to the warrants and the value assigned to the resulting beneficial conversion feature, were recorded as debt discounts on the consolidated balance sheet. The debt discounts are being amortized over the life of the corresponding convertible promissory notes using the effective interest method.

In connection with the note issuances, the Company paid investment banking fees of 13% of the gross proceeds of $100,000 of the offering. In addition, at completion of the offering, the placement agent will receive a five-year warrant to purchase a number of shares of common stock at $0.25 per share equal to 10% of the number of shares of common stock that may be issued upon the conversion of the notes plus accrued interest thereon. As of June 30, 2013, 84,800 of such warrant shares have been reflected as outstanding. The aforementioned cash fees and commissions, totaling $13,000 and the fair value of the warrants issued of $32,738, are recorded as deferred financing costs and are being amortized to interest expense utilizing the effective interest rate method over the life of the corresponding convertible promissory notes.

Long-term Convertible Debt

First 2012 Convertible Debt Issuance (Tranche A)

From February through May 2012, the Company issued $406,000 in convertible notes in a private placement convertible note offering. The notes accrue interest at 8% per annum and the interest is payable in quarterly installments on January 1, April 1, July 1, and October 1. The principal is due in full on August 21, 2013, with the Company having the option to extend the due date no later than February 21, 2014. The Company granted each lender warrants to purchase a number of shares of common stock equal to one and one-half times the advance amount (609,000 in total). One hundred fifty thousand of these warrants granted with $100,000 of the related notes have an adjusted exercise price of $0.31 per share. The remaining 459,000 warrants have an adjusted exercise price of $0.65 per share. All warrants have a 10 year term from issuance date. Also, if the warrant holder elects to exercise the warrant by means of a cashless exercise, the number of net shares to be issued will be based on a current fair value not less than $2.25 per share. If the Company elects to extend the due date, the Company shall issue the lender warrants to purchase a number of shares of common stock equal to 75% of the aggregate number of warrant shares issued to lender based on the same warrant terms as listed earlier. At the option of the lender, the outstanding principal and interest under the notes may be converted into shares of the Company’s common stock at an adjusted conversion price of $0.25 per share. In the event of default, the purchaser shall receive 60,000 warrants a month based on the same terms listed earlier for a maximum of 720,000 warrants. Additionally, this debt is senior to all other debt that was outstanding as of the issuance date. One hundred thousand dollars of this convertible debt is subordinate to the previously issued $306,000 portion of these debt issuances.

The Company paid a total of $8,109 in legal fees and $38,600 in investment banking fees related to these transactions. These fees are recorded as deferred financing costs, and are being amortized to interest expense utilizing the effective interest rate method over the life of the corresponding convertible promissory notes.

In addition to the aforementioned cash investment banking fees, the Company may be required to issue warrants to the investment bankers at 10% coverage of the number of warrants issued to investors, or 60,900 warrants associated with the $406,000 convertible debt issued during 2012. These warrant issuances are contingent upon the investors’ conversion of their debt to equity, would be issued at the time of the investors’ conversion, and would have a $1.00 exercise price and five-year term.

Upon issuance to the lenders, the fair value of the 609,000 warrants related to the $406,000 in convertible debt was estimated to be $539,966, utilizing a Black-Scholes pricing model and was recorded as a warrant derivative liability on the consolidated balance sheet. The fair value of the warrants exceeded the corresponding $406,000 of debt by $133,966 which was recorded immediately to interest expense. The debt discount is being amortized over the life of the corresponding convertible promissory notes.

In accordance with the anti-dilution provisions within the original debt agreement, the conversion price for $100,000 of these notes was adjusted from $1.00 per share to $0.25 per share during 2012. Due to the resulting beneficial conversion feature, an additional $30,000 debt discount was recorded with a corresponding increase to additional paid in capital.

In November 2012, the Company entered into a Note and Warrant Adjustment Agreement (“Agreement”) with debt holders of $306,000 of this convertible debt. Under the Agreement, the conversion price for $306,000 of convertible debt was adjusted from $1.00 per share to $0.25 per share and the exercise price on the related 459,000 warrants was reduced from $1.25 per share to $0.65 per share. This transaction was treated as a debt extinguishment. As such, $162,208 of unamortized discount and $9,340 related to the warrant modifications were expensed as loss on debt extinguishment. Due to the resulting beneficial conversion feature on the adjusted new notes, a $306,000 debt discount was recorded with a corresponding increase to additional paid in capital.

Second 2012 Convertible Debt Issuance (Tranche B)

During the period from August 10, 2012 to March 4, 2013, the Company issued $1,490,500 in a private placement offering of convertible promissory notes to certain accredited investors. The notes accrue interest at 6% per annum and such interest is payable at maturity. Each note will mature on the 3rd anniversary of its issuance date and is junior to Tranche A debt.

The convertible promissory notes may be converted at the option of the note holder into shares of the Company’s common stock at a conversion price of $0.25 per share. The debt principal and any accrued interest will automatically convert into shares of common stock at a conversion price of $0.25 per share, upon the earlier of a change of control of the Company or the Company earning $500,000 or more in gross revenue during any fiscal quarter. Also, if the Company sells an aggregate of $2,500,000 of common stock, the principal and interest will automatically convert into common stock at a price equal to the lesser of the price per share paid by the investors purchasing such stock at such first closing or $0.25 per share. This feature has been determined to not meet the criteria for being a derivative.

In connection with the note issuances, the Company granted each note holder, warrants to purchase a number of shares of common stock equal to the advance amount (1,490,500 in total). The warrants have an exercise price of $1.25 per share and have a 10 year term from their respective note issuance date. Upon issuance, the relative fair value of the 1,490,500 warrants related to the $1,490,500 in convertible debt was estimated to be $862,703. The relative fair value was determined utilizing a Black-Scholes pricing model. A beneficial conversion feature of $627,797 resulted from a conversion price of $0.25 while the estimated fair value of the common stock ranged from $1.23 to $0.88 per share. Both the value assigned to the warrants and the value assigned to the resulting beneficial conversion feature, were recorded as debt discounts. The debt discounts are being amortized over the life of the corresponding convertible promissory notes using the effective interest method.

In connection with the note issuances, the Company paid investment banking fees of 13% of the gross proceeds of the offering. In addition, at completion of the offering, the placement agent will receive a five-year warrant to purchase a number of shares of common stock at $0.25 per share equal to 10% of the number of shares of common stock that may be issued upon the conversion of the notes plus accrued interest thereon. As of June 30, 2013 and December 31, 2012, 632,716 and 586,696, respectively, of such warrant shares have been reflected as outstanding. The aforementioned cash fees and commissions, totaling $174,265, the fair value of the warrants issued of $585,886 and $3,000 of related legal costs, are recorded as deferred financing costs and are being amortized to interest expense utilizing the effective interest rate method over the life of the corresponding convertible promissory notes.

On February 1, 2013, one $25,000 convertible note was converted to 100,000 shares of common stock. On June 5, 2013, one $25,000 convertible note was converted to 100,000 shares of common stock. An additional 4,847 shares were issued as payment of $1,212 of accrued interest payable related to this note.

First 2013 Convertible Debt Issuance (Tranche C)

During the period from March 4, 2013 to May 20, 2013, the Company issued $340,000 in a private placement offering of convertible promissory notes to certain accredited investors. The notes accrue interest at 6% per annum and such interest is payable at maturity. Each note will mature on the 2nd anniversary of its issuance date and is junior to Tranche A and B debt.

The convertible promissory notes may be converted at the option of the note holder into shares of the Company’s common stock at a conversion price of $0.25 per share. The debt principal and any accrued interest will automatically convert into shares of common stock at a conversion price of $0.25 per share, upon the earlier of the notes’ maturity, a change of control of the Company or the Company earning $500,000 or more in gross revenue during any fiscal quarter. Also, if the Company sells an aggregate of $2,000,000 of common stock, the principal and interest will automatically convert into common stock at a price equal to the lesser of the price per share paid by the investors purchasing such stock at such first closing or $0.25 per share. This feature has been determined to not meet the criteria for being a derivative.

In connection with the note issuances, the Company granted each note holder warrants to purchase a number of shares of common stock equal to the advance amount (340,000 in total). The warrants have an exercise price of $1.25 per share and have a 10 year term from their respective note issuance date. Upon issuance, the relative fair value of the 340,000 warrants related to the $340,000 in convertible debt was estimated to be $173,773. The relative fair value was determined utilizing a Black-Scholes pricing model. A beneficial conversion feature of $166,227 resulted from a conversion price of $0.25 while the estimated fair value of the common stock was $0.76 to $0.88 per share. Both the value assigned to the warrants and the value assigned to the resulting beneficial conversion feature, were recorded as debt discounts on the consolidated balance sheet. The debt discounts are being amortized over the life of the corresponding convertible promissory notes using the effective interest method.

In connection with the note issuances, the Company paid investment banking fees of 13% on $240,000 of the gross proceeds of the offering. In addition, at completion of the offering, the placement agent will receive a five-year warrant to purchase a number of shares of common stock at $0.25 per share equal to 10% of the number of shares of common stock that may be issued upon the conversion of the notes plus accrued interest thereon. As of June 30, 2013, 107,520 of such warrant shares have been reflected as outstanding. The aforementioned cash fees and commissions, totaling $31,200 and the fair value of the warrants issued of $84,904, are recorded as deferred financing costs and are being amortized to interest expense utilizing the effective interest rate method over the life of the corresponding convertible promissory notes.

The following is a summary of the convertible notes:

Short-term Convertible Notes:

	2011 Debt		Tranche D				Total Short-term Debt

Balance at December 31, 2011 (face value of $16,948)	$	16,948	$	—		$	16,948

Balance at December 31, 2012 (face value of $16,948)	$	16,948	$	—		$	16,948

Face value of notes issued		—		100,000			100,000
Less: value assigned to warrants as debt discount		—		(45,489	)		(45,489	)
Less: debt discount from beneficial conversion feature		—		(54,511	)		(54,511	)
Net value at issuance		16,948		—			16,948
Plus: accretion of debt discount for the six months ended June 30, 2013		—		6,944			6,944
Less: conversion to equity		—		—			—
Balance at June 30, 2013, net (face value of $116,948)	$	16,948	$	6,944		$	23,892

Long-term Convertible Notes:

	Tranche A			Tranche B				Tranche C		Total Long-term Debt
Balance at December 31, 2011	$	—		$	—		$	—		$	—
Face value of notes issued		406,000			1,393,000			—			1,799,000
Less: value assigned to warrants as debt discount		(406,000	)		(809,442	)		—			(1,215,442	)
Less: debt discount from beneficial conversion
feature		—			(583,558	)		—			(583,558	)
Net value at issuance		—			—			—			—
Plus: accretion of debt discount for the year
ended December 31, 2012		247,373			142,212			—			389,585
Plus: loss on debt extinguishment due to change
in terms		162,208			—			—			162,208
Less: beneficial conversion feature due to change
in terms		(306,000	)		—			—			(306,000	)
Less: debt discount from resolution of contingent
conversion price adjustment		(30,000	)		—			—			(30,000	)
Less: conversion to equity		—			(50,000	)		—			(50,000	)
Balance at December 31, 2012, net (face value
$1,749,000)		73,581			92,212			—			165,793

Face value of notes issued		—			97,500			340,000			437,500
Less: value assigned to warrants as debt discount		—			(53,261	)		(173,773	)		(227,034	)
Less: debt discount from beneficial conversion
feature		—			(44,239	)		(166,227	)		(210,466	)
Net value at issuance		—			—			—			—
Plus: accretion of debt discount		258,231			276,473			106,444			641,148
Less: conversion to equity		—			(50,000	)		(75,000	)		(125,000	)
Balance June 30, 2013 (face
value $2,061,500)		331,812			318,685			31,444			681,941
Current maturities at June 30, 2013
(total face value $406,000)		(331,812	)		—			—			(331,812	)
Long-term portion (face value $1,655,500)	$	—		$	318,685		$	31,444		$	350,129

Related Party Convertible Notes

As of June 30, 2013 and December 31, 2012, convertible promissory notes outstanding, described above, that are held by related parties aggregated $300,000 and $150,000, respectively.

5. STOCKHOLDERS’ EQUITY

Common Stock Issuances & Redemptions

During the six months ended June 30, 2013, the Company issued 404,847 shares of unregistered common stock upon conversion of $100,000 of convertible promissory notes and related accrued interest payable of $1,212.

Stock Purchase Warrant Grants

For warrants granted to non-employees in exchange for services, the Company records the fair value of the equity instrument using the Black-Scholes pricing model unless the value of the services is more readily determinable.

During the six months ended June 30, 2013, the Company issued the following stock warrants:

In connection with convertible debt issuances (Tranches C and D) during the three months ended June 30, 2013, a total of 265,000 stock warrants were issued to investors. 165,000 of the warrants have an exercise price of $1.25 per share and a ten year term (Tranche C), and 100,000 warrants have an exercise price of $0.50 and a ten year term (Tranche D).

	2)	In connection with the convertible note issuance (Tranche C and D) during the three months ended June 30, 2013, 113,920 warrant shares with a $0.25 exercise price and five year term will be issued as investment banking fees at completion of the offering. The value of the warrants, based on a Black-Scholes model analysis, was estimated to be $54,018, and was recorded as deferred financing costs.

	3)	In connection with convertible debt issuances (Tranches B and C) during the three months ended March 31, 2013, a total of 272,500 stock warrants were issued to investors with an exercise price of $1.25 per share and a ten year term.

	4)	In connection with the convertible note issuances (Tranches B and C) during the three months ended March 31, 2013, 124,420 warrant shares with a $0.25 exercise price and five year term will be issued as investment banking fees at completion of the offering. The value of the warrants, based on a Black-Scholes model analysis, was determined to be $99,071, and was recorded as deferred financing costs.

The weighted average fair value for all warrants issued during the six months ended June 30, 2013 was $0.78.

The following table summarizes information about the Company’s outstanding warrants as of June 30, 2013:

					Weighted
			Weighted		Remaining
			Average Exercise		Contractual
	Stock Warrants		Price		Life (years)
Balance outstanding at December 31, 2012		3,815,264	$	1.07		7.47

Granted		775,840		0.85		8.79
Exercised		—		—		—
Forfeited/cancelled		—		—
Balance outstanding at June 30, 2013		4,591,104	$	1.03		7.26

Stock Option Grants

In 2011, the Company adopted the Omnibus Incentive Compensation Plan, or 2011 Stock Plan, which authorizes the issuance or transfer of up to 1,600,000 shares of common stock. Pursuant to the 2011 Stock Plan, the share reserve will automatically increase on the first trading day in January each calendar year, by an amount equal to the lesser of 20% of the total number of outstanding shares of common stock on the last trading day in December in the prior calendar year or 1,000,000 shares. At June 30, 2013, there are 3,600,000 shares reserved under the 2011 Stock Plan.

The 2011 Stock Plan allows for the issuance of incentive and non-qualified stock options and other stock-based awards. Generally stock options are exercisable for a term and price as determined by the board of directors, not to exceed a ten year term. Incentive stock options granted to an employee holding more than 10% of the total combined voting may not exceed a 5 year term.

During the six months ended June 30, 2013 and 2012, the Company granted 225,000 and 80,000 stock options respectively, which included options issued to Company officers (50,000 and -0-, respectively) and board members (80,000 and 80,000, respectively). For the three and six months ended June 30, 2013 and 2012, total stock-option compensation expense was $67,799 and $123,037, and $197,505 and $172,606 respectively. The remaining unrecognized stock compensation expense at June 30, 2013 totals $245,028 and is expected to be recognized over the next 3.5 years.

The following table summarizes information about the Company’s outstanding stock options:

			Weighted		Weighted
			Average		Average
	Stock		Exercise		Contractual		Intrinsic
	Options		Price		Life (Years)		Value
Outstanding at December 31, 2012		1,130,000	$	1.00		7.61	$	—
Granted		225,000		0.87		9.59		—
Exercised		—		—		—		—
Forfeited/cancelled		—		—		—		—

Balance at June 30, 2013		1,355,000	$	0.98		7.53	$	—

Exercisable at June 30, 2013		993,750	$	0.98		7.40	$	—

The assumptions used to value option and warrant grants during the six months ended June 30, 2013 and 2012 are as follows:

	Six Months Ended June 30, 2013			Six Months Ended June 30, 2012
Estimated per share fair value of stock		$0.76 - $0.88			$0.95
Dividend yield		0.0	%		0.0	%
Risk-free rate of return		0.80% - 2.06%			0.83% - 1.90%
Expected life in years		5-10 years			10 years
Expected volatility		115.5% - 115.6%			117.9%

6. EARNINGS (LOSS) PER SHARE

The following table provides a reconciliation of the numerators and denominators used in calculating basic and diluted earnings (loss) per share for the three and six months ended June 30, 2013 and 2012.

	Three Months Ended June 30, 2013				Three Months Ended June 30, 2012			Six Months Ended June 30, 2013		Six Months Ended June 30, 2012

Basic earnings (loss) per share calculation:

Net income (loss) to common stockholders	$	(1,038,504	)	$	(619,370	)	$	(2,091,227	)	$	(1,252,017	)
Weighted average of common shares outstanding		13,877,927			10,837,999			13,708,775			10,767,247
Basic net earnings (loss) per share	$	(0.07	)	$	(0.06	)	$	(0.15	)	$	(0.12	)

Diluted earnings (loss) per share calculation:

Net income (loss) to common stockholders	$	(1,038,504	)	$	(619,370	)	$	(2,091,227	)	$	(1,252,017	)
Weighted average of common shares outstanding		13,877,927			10,837,999			13,708,775			10,767,247
Stock options (1)		—			—			—			—
Stock warrants (2)		—			—			—			—
Convertible debt (3)		—			—			—			—
Diluted weighted average common shares outstanding		13,877,927			10,837,999			13,708,775			10,767,247
Diluted net income (loss) per share	$	(0.07	)	$	(0.06	)	$	(0.15	)	$	(0.12	)

(1)

For the three and six months ended June 30, 2013 and 2012, there were common stock equivalents attributable to outstanding stock options of 1,355,000 and 1,130,000, respectively. The stock options are anti-dilutive for the three and six months ended June 30, 2013 and 2012 and therefore, have been excluded from diluted earnings (loss) per share.

(2)

For the three and six months ended June 30, 2013 and 2012, there were common stock equivalents attributable to warrants of 4,591,104 and 1,835,567, respectively. The warrants are anti-dilutive for the three and six months ended June 30, 2013 and 2012 and therefore, have been excluded from diluted earnings (loss) per share.

(3)

For the three and six months ended June 30, 2013 and 2012, there were common stock equivalents attributable to conversion shares related to the convertible notes and related accrued interest of 9,349,808 and 857,107, respectively. The conversion shares are anti-dilutive for the three and six months ended June 30, 2013, and 2012, and therefore, have been excluded from diluted earnings (loss) per share.

7. SUBSEQUENT EVENTS

During the period from July 1, 2013 to August 14, 2013, the Company issued $50,000 in connection with the continuation of private placement offerings of convertible promissory notes (Tranche D) to certain accredited investors. The notes accrue interest at 12% per annum and such interest is payable at maturity. Each note will mature on the six month anniversary of its issuance date and is junior to all other debt.

In connection with the note issuance, the Company granted each note holder, warrants to purchase a number of shares of common stock equal to the advance amount. The warrants have an exercise price of $0.50 per share and have a 10 year term from their respective note issuance date.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Statements

The Securities and Exchange Commission, or SEC, encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. Certain statements that we may make from time to time, including, without limitation, statements contained in this Quarterly Report on Form 10-Q, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be made directly in this Quarterly Report, and they may also be made a part of this Quarterly Report by reference to other documents filed with the SEC, which is known as “incorporation by reference.”

Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among other things: our need for additional capital to fund our sales and marketing efforts, continued work on our research and development programs; our inability to further identify, develop and achieve commercial success for new products and technologies; the development of competing diagnostic products; our ability to protect our proprietary technologies; patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading Item 1A “Risk Factors” in this Quarterly Report on Form 10-Q.

In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report or in any document incorporated by reference might not occur. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this Quarterly Report or the date of the document incorporated by reference in this Quarterly Report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable law. All subsequent forward-looking statements attributable to Vertical Health Solutions, Inc., referred to herein as VHS, VHS’s wholly-owned subsidiary, OnPoint Medical Diagnostics, Inc., referred to herein as OnPoint, or to any person authorized to act on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

Overview

OnPoint was founded to commercialize MRI quality assurance software and technologies originally developed by Mayo Clinic. The company is dedicated to leveraging technology and intelligent systems to assist the global healthcare industry in delivering the highest quality medical images possible – safely, consistently and efficiently. OnPoint's enterprise quality assurance solution is deployed in the cloud and delivered in a “Software as a Service”, or SaaS, utility computing model, which provides anytime, anywhere access to the technology.

Our flagship product for MRI is focused on automating the quality control measures required for accreditation by American College of Radiology, with real-time dashboards, analytics and trending to make sure scanners are providing the best possible images of patients.

Through June 30, 2013, we have signed contracts with customers which have or will result in revenue totaling $185,220. Since our inception in February 2009, we have incurred losses and negative cash flows from operations, and such losses have continued subsequent to June 30, 2013. As of June 30, 2013, we had an accumulated deficit of $10,958,481 and anticipate incurring additional losses while we ramp up our sales and marketing efforts. We expect to spend significant resources over the next several years to secure new customers, develop strategic partnerships, and to fund future research and development. In order to achieve profitability, we must continue to develop software products and technologies that can be commercialized by us or through existing and future collaborations.

Marketing and Sales

Our software is sold on a per scanner per month basis, with appropriate volume discounts. It is deployed in the cloud so activation costs for new customers are minimal and our software, implementation, training, sales, marketing and customer support will leverage technology and automation. Currently, we can get a new customer fully implemented and trained remotely in less than one hour. This allows us to offer programs such as 30-day free trials for our software to the market.

We plan to continue to sell primarily through an inside sales organization and channel partners, as this approach minimizes our cost of sales and allows centralized control for customizing and delivering unique marketing programs.

As of June 30, 2013, the OnPoint product was being used by 52 hospitals and imaging centers in 20 states, with approximately 108 scanners sending images to the OnPoint cloud. We are developing strategic partnerships to assist with the sales and marketing of our products. We have successfully completed pilots with two significant partnerships. Additional capital will be required to fully-engage with these partners and execute the agreed upon next steps.

We intend to develop additional models for MRI as well as quality control systems for other modalities (Computed Tomography, or CT, Mammography, Ultrasound and others), all of which have similar accreditation requirements and quality control challenges.

Financings

During the six months ended June 30, 2013, we issued $537,500 in convertible promissory notes. $97,500 of these notes (Tranche B) has a 3-year term and $340,000 of these notes (Tranche C) has a two year term. Tranches B and C accrue interest at a rate of 6% per annum. $100,000 of these notes (Tranche D) has a six month term, and accrue interest at a rate of 12% per annum. These notes are convertible into common stock at $0.25 per share (Tranches B and C), and $0.125 per share (Tranche D). Interest is due at maturity. These notes will mature on various dates in 2013, 2015 and 2016. In connection with the issuance of these notes, we also issued to the investors ten-year warrants to purchase, in the aggregate, 537,500 shares of our common stock. These warrants have an exercise price of $1.25 per share (Tranches B and C) and $0.50 per share (Tranche D).

Results of Operations

Three months ended June 30, 2013 compared to June 30, 2012

Revenue and Costs of Revenues

For the three months ended June 30, 2013 and 2012, we recognized revenue of $16,083 and $3,666, respectively, on SaaS contracts, which have terms of 12 to 36 months. For the three months ended June 30, 2012, we also recognized $50,000 in service contract revenue for services performed during the quarter. Costs of revenues for the quarter ended June 30, 2013 and 2012 was $65,775 and $71,378, respectively. Costs of revenues for the three months ended June 30, 2013 consisted of employee compensation allocated to revenue generating efforts of $22,377; $25,000 of royalty payments due to Mayo; and software amortization expense of $18,398. The increase in SaaS contract related revenue resulted from an increase in new and renewed software contracts. The decrease in costs of revenues in the current three-month period compared to the prior year comparable period resulted primarily from a decrease in royalty costs recognized during the quarter.

Operating Expenses

Our general and administrative expenses consist primarily of compensation paid to employees and related benefit expenses for business development, financial, legal and other administrative functions. In addition, we incur external costs for professional fees for legal, patent and accounting services. We expect that our general and administrative expenses, both internal and external, will increase as we continue with our increased sales and marketing efforts.

Research and Development Expenses. Our research and development expenses were $75,324 for the three months ended June 30, 2013 and $27,095 for the three months ended June 30, 2012. The Company had previously capitalized research and development costs related to the development of the Company’s software product after technological feasibility was proven. Our current research and development efforts are focused on improving our initial design and platform and developing a streamlined version thereon, called OnPoint Express and these costs are being expensed as incurred.

Selling, General and Administrative Expenses. Our general and administrative expenses were $369,322 for the three months ended June 30, 2013 compared to $412,359 for the three months ended June 30, 2012. Consulting expense increased in the current three month period over the comparable prior year period, primarily due to the addition of our Chief Revenue Officer, who was paid $37,500 in consulting fees during the quarter. Stock option expense decreased from $120,909 during the three months ended June 30, 2012 to $67,799 in the current quarter as stock options issued in the prior year period were issued and became vested upon issuance and were expensed in the prior year comparable period. Marketing expense decreased $17,460 for the three months ended June 30, 2013 compared to the comparable prior year period.

Interest Expense. Interest expense was $544,166 for the three months ended June 30, 2013 compared to $182,237 for the three months ended June 30, 2012. Increases are primarily attributable to increases in amortization of both warrant and beneficial conversion feature discounts and deferred debt financing costs from additional debt issued over the past year.

Components of interest expense consisted of the following for the three and six months ended June 30, 2013 and 2012, respectively:


		Three Months Ended June 30, 2013		Three Months Ended June 30, 2012		Six Months Ended June 30, 2013		Six Months Ended June 30, 2013
Components of interest expense:
Accrued interest on all debt	$	32,296	$	22,010	$	61,590	$	39,484
Amortization of warrant and beneficial conversion feature
discount on convertible notes and long-term promissory notes		372,831		79,640		648,092		108,989
Amortization of deferred debt financing costs		139,039		18,422		234,741		32,314
Interest charge recognized on warrant derivative liability		—		62,165		—		133,965
Other interest expense		—		—		7,076		—
	$	544,166	$	182,237	$	951,499	$	314,752

Six months ended June 30, 2013 compared to June 30, 2012

Revenue and Costs of Revenues

For the six months ended June 30, 2013 and 2012, we recognized revenue of $29,446 and $5,539, respectively, on SaaS contracts, which have terms of 12 to 36 months. For the six months ended June 30, 2012, we also recognized $60,000 in service contract revenue for services performed during the quarter. Costs of revenues for the six months ended June 30, 2013 and 2012 was $134,212 and $91,579, respectively. Costs of revenues for the six months ended June 30, 2013 consisted of employee compensation allocated to revenue generating efforts of $46,216; $50,000 of royalty payments due to Mayo; and software amortization expense of $36,796. The increase in SaaS revenue resulted from an increase in new and renewed software contracts. The increase in costs of revenues in the current six-month period compared to the prior year comparable period resulted primarily from an increase in related employee compensation costs allocated to costs of revenues.

Operating Expenses

Research and Development Expenses. Our research and development expenses were $182,105 for the six months ended June 30, 2013 and $131,911 for the six months ended June 30, 2012. The Company had previously capitalized research and development costs related to the development of the Company’s software product after technological feasibility was proven. Our current research and development efforts are focused on improving our initial design and platform and developing a streamlined version thereon, called OnPoint Express and these costs are being expensed as incurred.

Selling, General and Administrative Expenses. Our general and administrative expenses were $852,857 for the six months ended June 30, 2013 compared to $799,351 for the six months ended June 30, 2012. The primary reasons for the overall increase were as follows: 1) consulting expense increased in the current six month period over the comparable prior year period, primarily due to the addition of our Chief Revenue Officer, who was paid $96,100 in consulting fees during the six months ended June 30, 2013, 2) stock option expense increased from $172,606 during the six months ended June 30, 2012 to $197,506 in the current six month period as stock options issued in the current year period were issued and became vested upon issuance and were expensed in the current year comparable period, and 3) marketing expense decreased $54,490 for the six months ended June 30, 2013 compared to the comparable prior year period.

Interest Expense. Interest expense was $951,499 for the six months ended June 30, 2013 compared to $314,752 for the six months ended June 30, 2012. Increases are primarily attributable to increases in amortization of both warrant and beneficial conversion feature discounts and deferred debt financing costs from additional debt issued over the past year.

Liquidity and Capital Resources

Summary

At June 30 2013, we had cash of $64,609 and negative working capital of $630,988. For the six months ended June 30, 2013, we have funded substantially all of our operations and capital expenditures through private placements of convertible notes totaling $537,500. Based on our current operating plan, the Company has enough funds for operations to September 30, 2013.

Operating Cash Flows

Operating activities used $959,915 and $702,590 of cash during the six months ended June 30, 2013 and 2012, respectively; a decrease of $257,325. We recorded a net loss of $2,091,227, which included non-cash adjustments of $1,120,244 and a net change to operating assets and liabilities of $11,068 during the current quarter; compared to a net loss of $1,252,017, which included non-cash operating adjustments of $501,117 and a net change to operating assets and liabilities of $48,310 during the six months ended June 30, 2012. Significant increases in cash operating expenses included: (1) increased consulting expense of $167,050, and (2) increased legal and accounting expense of $48,935.

Investing Cash Flows

We used $6,829 of cash in investing activities during the six months ended June 30, 2013, compared to investing activities providing $25,299 of cash during the comparable prior year period. We purchased $6,829 of property and equipment during the six months ended June 30, 2013.

Financing Cash Flows

Financing activities provided $480,950 and $539,441 of cash during the six months ended June 30, 2013 and 2012, respectively. Financing activities consisted of proceeds of convertible debt issuances of $537,500 and $406,000, less cash paid for debt financing costs of $56,550 and $46,709 during the six months ended June 30, 2013 and 2012, respectively. Also, in 2012, the Company issued $180,150 in common stock compared to no stock being issued in 2013.

Convertible Debt Conversions, Maturities and Related Payment Obligations

The outstanding convertible notes issued in the first 2012 convertible debt issuance (Tranche A) totaling $406,000 mature in August 2013, and interest is payable quarterly. At the option of the Company, these notes can be extended until February 2014. The Company intends to exercise its option to extend the maturity these notes to February 2014. The principal and accrued interest on the outstanding notes issued in the second 2012 and 2013 convertible debt offerings (Tranches B and C) totaling $1,655,500 are payable at maturity in March 2015 through March 2016. The principal and accrued interest on the outstanding notes issued in June 2013 (Tranche D) totaling $100,000 are payable at maturity in December 2013.

During the three months ended June 30, 2013, three convertible notes totaling $100,000 were converted to 400,000 shares of common stock. In addition, $1,212 of accrued interest payable was converted to 4,847 shares of common stock in conjunction with one of these conversions.

Royalty Payment Obligations

Under our existing license agreement with Mayo, we have an obligation to pay a minimum royalty of $100,000 per year to Mayo starting in 2012, and each year thereafter. As of June 30, 2013, we have accrued $200,000 of such royalty payments. At June 30, 2013, all 2011 and 2012 payments, totaling $150,000, were past due. However, we have since negotiated revised payment terms with Mayo on the Company’s outstanding balance due for 2011 and 2012 royalty payments. Interest to be paid on the $150,000 outstanding balance related to 2011 and 2012 royalty payments is calculated based on Prime plus 2.00%, or 5.25% per annum. The revised payment terms require monthly payments beginning in August 2013 such that $150,000 of the balance due will be paid by December 31, 2013, and interest thereon to be paid by January 31, 2013.

Funding Ongoing Operations

We continue to expend significant cash resources to expand our sales and marketing efforts and ongoing research and development activities. We expect that expenditures in connection with these activities will require additional funding to achieve our strategic and operational objectives.

In order to fully launch the sales and marketing efforts to penetrate the marketplace with our product, to fully fund ongoing research and development efforts, and build our internal operations, we are seeking to raise additional capital during the remainder of 2013. A capital raise could include the securing of funds through new strategic partnerships or collaborations, the sale of common stock or other equity securities or the issuance of debt. We require operating capital from external sources such as strategic partnerships or collaborations, the sale of common stock or other equity securities or the issuance of debt to sustain the business as we continue to increase our sales and marketing efforts and continue to secure new customers. We cannot assure you that any such capital raising transaction will be available to us as needed, or on favorable terms. We are subject to those risks associated with any software company. In addition, we operate in an environment of rapid technological change and we are largely dependent on the services of our employees and consultants. We cannot assure you that future development projects will be successful, that future products will be commercially viable, or that we will be able to attract and retain the necessary employees and consultants to complete development and commercialize additional products.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, we evaluate our judgments and estimates, including those related to long-lived assets, accrued liabilities, share-based payments and income taxes. We base our judgment and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 to our financial statements, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements:

Software Development Costs

Minimum Royalty Payments

The Company’s policy is to recognize the minimum royalty payments based on the occurrence of the Company’s sales activity. If it is determined that the minimum obligation will not be met, an accrual will be recorded accordingly. During the quarter ended June 30, 2013, the Company determined that the minimum obligation would not be met through a percentage of our sales and therefore, during the three month period ended June 30, 2013, the Company has accrued $25,000 of royalty payments. The total accrual for unpaid royalties was $200,000 at June 30, 2013.

Revenue Recognition

The Company is a development stage company and has not generated significant revenue since inception (February 1, 2009). Software subscription revenue under existing contracts is recorded as deferred revenue upon execution of a software subscription agreement. Revenue is then recognized on a straight-line basis over the life of the subscription agreement, which is typically 12 to 36 months.

Income Taxes

We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the tax consequences of temporary differences between the tax basis of assets and liabilities and their carrying amounts for financial reporting purposes using enacted tax rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

We have recorded a full valuation allowance against our deferred tax assets at June 30, 2013 and December 31, 2012.

Stock-Based Compensation

We recognize expense for stock-based compensation based on the fair value of the awards granted. The fair value of stock options is estimated at the date of grant using the Black-Scholes option valuation model. We make assumptions about complex and subjective variables and the related tax impact. These variables include, but are not limited to, our stock price volatility and stock option exercise behaviors. For volatility, we are currently using comparable public companies as a basis for our estimate. We recognize the compensation cost for stock-based awards on a straight-line basis over the requisite service period for the entire award.

Debt Issued with Warrants

We account for the issuance of debt and related warrants by allocating the debt proceeds between the debt and warrants based on the relative estimated fair values of the debt security without regard for the warrants and the estimated fair value of the warrants themselves. The amount allocated to the warrants would then be reflected as both an increase to equity, and as a debt discount that would be amortized over the term of the debt. However, in circumstances where warrants must be accounted for as a liability, the full estimated fair value of the warrants is established as both a liability and a debt discount. In some cases, if the value of the warrants is greater than the principal amount received, an immediate interest expense charge is recorded for the excess.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

We have not entered into and do not expect to enter into financial instruments for trading or hedging purposes. We do not currently anticipate entering into interest rate swaps and/or similar instruments. Our primary market risk exposure with regard to financial instruments is to changes in interest rates, which would impact interest income earned on such instruments. We have no material currency exchange or interest rate risk exposure as of June 30, 2013. Therefore, there will be no ongoing exposure to a potential material adverse effect on our business, financial condition or results of operation for sensitivity to changes in interest rates or to changes in currency exchange rates.

ITEM 4. CONTROLS AND PROCEDURES

(a) Disclosure Controls and Procedures. Our chief executive officer and chief financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2013. Based on this evaluation, our chief executive officer and our chief financial officer concluded that, as of June 30, 2013, our disclosure controls and procedures were not effective to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our chief executive officer and our chief financial officer as appropriate to allow timely decisions regarding required disclosure.

As reported in our assessment of the effectiveness of our internal controls over financial reporting as of December 31, 2012, included in “Item 9A. Controls and Procedures” of Form 10-K for the year ended December 31, 2012, the following material weaknesses existed:

1. The Company has insufficient internal personnel resources and technical accounting and reporting expertise within the Company’s financial closing and reporting functions to completely address complicated convertible debt transactions.

2. Due to our small size, the Company did not maintain effective internal controls to assure proper segregation of duties as the same employee was responsible for both initiating and recording of transactions, thereby creating a segregation of duties weakness.

No remediation of these internal control weaknesses has been performed to date due to the limited discretionary funds available to the Company at this time.

(b) Changes in Internal Controls. There were no significant changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), identified in connection with the evaluation of such internal control that occurred during our last fiscal quarter, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company’s management knows of no material existing or pending legal proceedings or claims against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. To the Company’s knowledge, no director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than five percent (5%) of the Company’s securities, or any associate of any such director, officer or security holder is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries in reference to pending litigation.

ITEM 1A. RISK FACTORS

Risks Related To Our Business and Industry

Our auditors have expressed substantial doubt about our ability to continue as a going concern.

Our audited financial statements for the year ended December 31, 2012, were prepared under the assumption that we will continue our operations as a going concern. We have a limited operating history with no significant revenues and have incurred cumulative net losses of $10,958,481 through June 30, 2013. As a result, our independent registered public accounting firm in their audit report on our 2012 Financial Statements has expressed substantial doubt about our ability to continue as a going concern. Continued operations are dependent on our ability to complete equity or debt formation activities or to generate profitable operations. Given general economic uncertainties, such capital formation activities may not be available or may not be available on reasonable terms. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we cannot continue as a viable entity, our stockholders may lose some or all of their investment in us.

We are a development stage company. We have incurred losses since inception and expect to incur significant net losses in the foreseeable future and may never become profitable.

We are in the development stage and have a limited operating history for you to consider in evaluating our business and prospects. We have not yet generated significant sales or net income. We have incurred operating losses since inception and expect to incur significant net losses in the foreseeable future. There can be no assurance that we will be able to generate significant revenues from the sales of current or future products. Our ability to achieve profitability will depend on, among other things, our success in selling our products, managing our expense levels and quickly integrating newly-hired personnel, including management.

We will need additional capital to fund our operations.

We are seeking to raise additional capital in 2013 to fund our operations and future development. A capital raise could include the securing of funds through new strategic partnerships or collaborations, the sale of common stock or other equity securities or the issuance of debt. In the event we do not enter into a corporate collaboration or undertake a financing of debt or equity securities, we may not have sufficient cash on hand to fund our operations. We can give no assurances that we will be able to enter into a strategic transaction or raise any additional capital or if we do, that such additional capital will be sufficient to meet our needs, or on terms favorable to us.

If we are unable to raise additional funds, we will need to do one or more of the following:

•

further delay, scale-back or eliminate some or all of our product development programs;

•

attempt to sell our company;

•

cease operations; or

•

declare bankruptcy.

Expanding sales and marketing activities and continuing our development efforts will require significant expenditures of capital. The actual amount and timing of capital requirements may differ materially from our estimates, depending on the demand for our products and as a result of new market developments and opportunities. We may determine that it is necessary or desirable to obtain financing for such requirements through borrowings or the issuance of debt or equity securities. Debt financing would increase leverage, while equity financing may dilute the ownership of stockholders. There can be no assurance as to whether, or as to the terms on which, we will be able to obtain such financing. Any failure to generate sufficient funds from operations or equity or debt financing to meet our capital requirements could have a material adverse effect on our business, financial condition and results of operations.

At June 30, 2013, we had cash and cash equivalents of $64,609 and negative working capital of $630,988. Through June 30, 2013, we have funded substantially all of our operations and capital expenditures through private placements of equity and convertible notes securities. Based on our operating plan, the Company has enough funds for operations through September 30, 2013.

Our success depends upon maintaining our license to critical intellectual property.

Our success depends upon our maintaining the license with Mayo Foundation for Medical Education and Research for the technology which comprises our product. Future defaults by us could result in the termination of the license which is critical to our business.

Our success is dependent on market acceptance of our products.

Our ability to gain market acceptance and to grow will largely depend upon our success in effectively and efficiently communicating product benefits to the key buyer groups and distinguishing our products from other similar products. To gain market share, we must also overcome the established relationships between other service providers and customers. We cannot assure you that we will be able to achieve success, to gain market acceptance and to grow. Our failure to achieve market acceptance of our products would have a material adverse effect on our business, financial condition and results of operations.

Our future revenues are unpredictable and we expect our operating results to fluctuate from period to period.

Our limited operating history and the uncertain nature of the market make it difficult for us to accurately forecast our future revenues in any given period. We have limited experience in financial planning for our business on which to base our planned operating expenses. If our revenues in a particular period fall short of our expectations, we will likely be unable to quickly adjust our spending in order to compensate for that revenue shortfall. As a result, our operating results would be adversely affected. Our operating results are likely to fluctuate substantially from period to period as a result of a number of factors, many of which are beyond our control. These factors include:

•

the amount and timing of operating costs and capital expenditures relating to expansion of our operations;

•

the rate at which potential users adopt our products;

•

the announcement or introduction of new or enhanced products by our competitors;

•

our ability to attract and retain qualified personnel; and

•

the pricing policies of our competitors.

Our business model is evolving and unproven.

Our business model is unproven and is likely to continue to evolve. Accordingly, our business model may not be successful and may need to be changed. Our ability to generate significant revenues will depend, in large part, on our ability to successfully market our products to potential users who may not be convinced of the need for our products and services or may be reluctant to rely upon third parties to develop and provide these products. We intend to continue to develop our business model as our market continues to evolve.

We need to increase brand awareness.

Due to a variety of factors, our opportunity to achieve and maintain a significant market share may be limited. Developing and maintaining awareness of our brand name, among others, is critical. Further, the importance of brand recognition will increase as competition in our market increases. Successfully promoting and positioning our brand will depend largely on the effectiveness of our marketing efforts and our ability to develop industry-leading products at competitive prices. Therefore, we may need to increase our financial commitment to creating and maintaining brand awareness. If we fail to successfully promote our brand name or if we incur significant expenses promoting and maintaining our brand name, it could have a material adverse effect on our results of operations.

We compete in highly competitive markets.

The market for MRI quality assurance software solutions is new and currently just evolving. Overall, the quality control market within the medical industry is fragmented, with much of the work still being performed manually. As such our primary competitor today is the manual process performed by technologists and recorded in a paper-based log book. The only direct competitor with a software solution is Radiological Imaging Technology, who does not offer a cloud-based solution. Potential competitors include large, multi-national companies who have a larger installed base of users, longer operating histories, greater name recognition and substantially greater technical, marketing, and financial resources.

Although we believe we will compete favorably in our market, new competitors could develop that may have longer operating histories, established ties to customers, greater brand awareness and well-accepted products. These competitors in the market space could have greater financial, technical and marketing resources. Our ability to compete depends, in part, upon a number of factors outside our control, including the ability of our competitors to develop alternatives that are competitive with our products.

Our success depends, in part, upon our intellectual property rights.

Our success depends, in part, upon our intellectual property rights. We will also rely upon a combination of trade secret, nondisclosure and other contractual arrangements, and copyright and trademark laws to protect our proprietary rights. We will enter into confidentiality agreements with our employees and contractors and limit access to and distribution of our proprietary information. There can be no assurance that such steps will be adequate to deter misappropriation of our proprietary information or that we will be able to detect unauthorized use and take appropriate steps to enforce our intellectual property rights.

Our ability to manage growth will affect our management systems, infrastructure and resources.

Our ability to successfully offer products and implement our business plan in the market requires an effective planning and management process. We are in the process of expanding our operations, and we intend to increase our headcount substantially. Expanding our operations and experiencing rapid growth will place a significant strain on our management systems, infrastructure and resources. To manage anticipated growth, we will need to develop and improve our operational, financial, accounting and other internal systems. In addition, our future success will depend in large part upon our ability to recruit, train, motivate and retain managers and other employees and maintain product quality. If we are unable to manage anticipated growth effectively, it could have a material adverse effect on the quality of our products and our business, financial condition, and results of operations.

We depend on key personnel and will need to attract and retain additional personnel.

Our success will depend in large part upon the key personnel we intend to hire. At this time, we have our Chief Executive Officer, William Cavanaugh, our Interim Chief Financial Officer, Jim Marolt, our Chief Revenue Officer, Ken Roos, our Chief Technology Officer, Chris Hafey, and our Director of Product Management, Brian Diaz, in place as part of our management team. We intend to recruit other key members of the management team. If we do not quickly and efficiently integrate these key personnel into our management and culture, our business could suffer. Our future success depends on our ability to identify, attract, hire, train, retain and motivate highly skilled executive, technical, managerial, sales and marketing and business development personnel. We intend to hire additional executive, technical, sales, and marketing, business development and administrative personnel during the next year. Competition for qualified personnel is intense. If we fail to successfully attract, assimilate and retain a sufficient number of qualified executive, technical, managerial, sales and marketing, business development and administrative personnel, our business could suffer. The loss of the services of these key employees could have an adverse effect on our business. In addition, if one or more of these key employees resigns to join a competitor or to form a competing company, the loss of such employees and any resulting loss of existing or potential customers to such competitor could have a material adverse effect on our business, financial condition and results of operations. In the event of the loss of any such personnel, there can be no assurance that we would be able to prevent the unauthorized disclosure or use of our practices or procedures by such personnel. Although we intend to have key employees execute agreements containing confidentiality covenants, there can be no assurance that courts will enforce such covenants as written or that the agreements will deter conduct prohibited by such covenants.

Our organizational documents limit director liability.

Our Articles of Incorporation and Bylaws provide for indemnification of directors to the full extent permitted by law, eliminate or limit the personal liability of our directors and shareholders of monetary damages for certain breaches of fiduciary duty. Such indemnification may be available for liabilities arising in connection with the Merger. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling our business pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

We may be subject to potential product liability and other claims and we may not have the insurance or other resources to cover the costs of any successful claims.

Defects in our products could subject us to potential product liability claims that our products caused some harm to the human body. Our product liability insurance may not be adequate to cover future claims. Product liability insurance is expensive and, in the future, may not be available on terms that are acceptable to us, if it is available at all. Plaintiffs may also advance other legal theories supporting their claims that our products or actions resulted in some harm. A successful claim brought against us in excess of any insurance coverage that we have could significantly harm our business and financial condition.

Risks Related to Our Common Stock

We expect an illiquid market for our common stock.

The shares for our common stock are currently subject to very limited trading. We are unable to predict if a trading market will develop and be sustained, but we expect any such market to involve limited liquidity for some period of time.

We expect the market price for our common stock to be volatile.

The price of our common stock is expected to be volatile and an investment in our common stock could decline in value.

The market price of our common stock and the market prices for securities of software or medical imaging companies in general, are expected to be highly volatile. The following factors, in addition to other risk factors described in this Quarterly Report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control:

•

announcements of technological innovations and discoveries by us or our competitors;

•

developments concerning any research and development, manufacturing, and marketing collaborations;

•

new products or services that we or our competitors offer;

•

actual or anticipated variations in operating results;

•

the initiation, conduct and/or outcome of intellectual property and/or litigation matters;

•

changes in financial estimates by securities analysts;

•

conditions or trends in software or other medical imaging industries;

•

regulatory developments in the United States and other countries;

•

changes in the economic performance and/or market valuations of other software or medical imaging companies;

•

our announcement of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

•

additions or departures of key personnel;

•

global unrest, terrorist activities, and economic and other external factors; and

•

sales or other transactions involving our common stock.

The stock market in general has recently experienced relatively large price and volume fluctuations. In particular, market prices of securities of software companies have experienced fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Prospective investors should also be aware that price volatility may be worse if the trading volume of our common stock is low.

We do not expect to pay cash dividends in the foreseeable future.

No dividends have ever been paid by us and it is anticipated that any future profits received from operations will be retained for operations. We do not anticipate the payment of cash dividends on our capital stock in the foreseeable future, and any decision to pay dividends will depend upon our profitability at the time, cash available, and other factors. Therefore, no assurance can be given that there will ever be any such cash dividend or distribution in the future.

Because OnPoint became a public company as a result of a reverse merger and not a public offering, we may not attract the attention of major brokerage firms and, as a public company, will incur substantial expenses.

OnPoint became a publicly-traded company through a merger with a public shell company and, accordingly, will be subject to the information and reporting requirements of the United States securities laws. The costs to public companies of preparing and filing annual and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders will cause our expenses to be higher than they would be if it were a privately-held company. Security analysts of major brokerage firms may not provide coverage of our business. No assurance can be given that brokerage firms will undertake to make a market for our common stock in the future.

Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our operating results and financial condition could be harmed.

We are required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, which requires annual management assessments of the effectiveness of our internal controls over financial reporting. For the year ended December 31, 2012, we identified two material weaknesses related to our internal controls. Due to our limited resources at this time, we have not remediated these material weaknesses.

Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and operating results. In addition, current and potential stockholders could lose confidence in our financial reporting, which could have a material adverse effect on our stock price.

Our compliance with the Sarbanes-Oxley Act and SEC rules concerning internal controls will be time consuming, difficult and costly.

As a reporting company, it will be time consuming, difficult and costly for us to develop and implement the internal controls and reporting procedures required by Sarbanes-Oxley. We will need to hire additional financial reporting, internal control, and other finance staff in order to develop and implement appropriate internal controls and reporting procedures. If we are unable to comply with Sarbanes-Oxley’s internal controls requirements, we may not be able to obtain the independent accountant certifications that Sarbanes-Oxley Act requires publicly-traded companies to obtain.

As shares of our common stock become eligible for sale their sale could depress the market price of our common stock.

As shares of our common stock become gradually available for resale in the public market, the supply of our common stock will increase, which could decrease our market price. Some or all of the shares of our common stock may be offered from time to time in the open market pursuant to Rule 144 (or pursuant to a registration statement, if one is effective), and these sales may have a depressive effect on the market for the shares of our common stock. In general, a person who has held restricted shares for a period of one year from the filing of the Company’s Form 8-K relating to the Merger containing the Form 10 information may, sell our common stock into the market.

Our common stock will be considered “a penny stock” and may be difficult to sell.

The SEC has adopted regulations that generally define “penny stock” to be an equity security that has a market or exercise price of less than $5 per share, subject to specific exemptions. Initially, the market price of our common stock is less than $5 per share and therefore is designated a “penny stock” under SEC rules. This designation requires any broker or dealer selling our common stock to disclose certain information about the transaction, obtain a written agreement from the investor and determine that the investment in our common stock by the investor is a reasonably suitable investment for such investor. These rules may restrict the ability of brokers or dealers to sell our common stock and, as a result, may affect the ability of investors to sell their shares. In addition, unless and until our common stock is listed for trading on a national securities exchange, investors may find it difficult to obtain accurate quotations of the price of our common stock and may experience a lack of buyers to purchase such stock or a lack of market makers to support the stock price. Resale restrictions on transferring “penny stocks” are sometimes imposed by some states, which may make transactions in our stock more difficult and may reduce the value of your investment.

Substantial future issuances of our common stock could depress our stock price.

The market price for our common stock could decline, perhaps significantly, as a result of issuances of a large number of shares of our common stock in the public market or even the perception that such issuances could occur. Sales of a substantial number of these shares of our common stock, or the perception that holders of a large number of shares intend to sell their shares, could depress the market price of our common stock.

Shareholders will experience additional dilution upon the conversion of the convertible notes or the exercise of warrants or options.

As of June 30, 2013, we have 9,349,808 shares of common stock issuable upon conversion of our convertible promissory notes and related accrued interest (at an assumed conversion price of $0.125 to $0.66 per share), 4,591,104 shares of common stock issuable upon exercise of outstanding warrants and 1,355,000 shares of common stock issuable upon exercise of outstanding options. In addition, we are entitled to reserve a pool of stock options representing approximately 20% of the shares of our common stock for the Employee Stock Option Pool, pursuant to our 2011 Omnibus Incentive Compensation Plan. The Employee Stock Option Pool will automatically increase each year such that the total number of shares available for issuance under the 2011 Omnibus Incentive Compensation Plan is equal to 20% of the fully-diluted shares as of the date of such increase.

If the holders of those convertible notes, warrants, or options convert or exercise their rights, you may experience dilution in the net tangible book value of your common stock.

Our Directors and officers, as well as certain stockholders, will have a high concentration of common stock ownership.

As of June 30, 2013, our officers and directors beneficially owned approximately 24.2% of our outstanding common stock (assuming none of our remaining notes are converted). Such a high level of ownership by such persons may have a significant effect in delaying, deferring or preventing any potential change in control of us. Additionally, as a result of their high level of ownership, our officers, directors and such stockholders might be able to strongly influence the actions of our board of directors, and the outcome of actions brought to our stockholders for approval. Such a high level of ownership may adversely affect the voting and other rights of our stockholders.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Long-Term Debt Financing

During the period from April 1, 2013 to June 30, 2013, the Company issued $265,000 in a private placement offering of convertible promissory notes to certain accredited investors. $165,000 of the notes (Tranche C) accrue interest at 6% per annum and such interest is payable at maturity. These notes will mature on the third anniversary of its issuance date. $100,000 of the notes (Tranche D) accrue interest at 12% per annum and such interest is payable at maturity in December 2013. These notes are junior to all other debt.

The convertible promissory notes may be converted at the option of the note holder into shares of the Company’s common stock at a conversion price of $0.25 per share (Tranche C), or $0.125 per share (Tranche D). The debt principal and any accrued interest will automatically convert into shares of common stock at a conversion price of $0.25 per share (Tranche C), or $0.125 (Tranche D), upon the earlier of the maturity of the Notes (Tranches C and D), a change of control of the Company (Tranches C and D) or the Company earning $500,000 or more in gross revenue during any fiscal quarter (Tranche C). Also, if the Company sells an aggregate of $2,000,000 (Tranches C and D) of common stock, the principal and interest will automatically convert into common stock at a price equal to the lesser of the price per share paid by the investors purchasing such stock at such first closing or $0.25 per share (Tranche C) or $0.125 per share (Tranche D).

In connection with the note issuance, the Company granted each note holder, warrants to purchase a number of shares of common stock equal to the advance amount (265,000 in total). The warrants have exercise prices of $1.25 per share (Tranche C) and $0.50 per share (Tranche D) and have a 10 year term from their respective note issuance date.

In connection with $165,000 of the note issuances, the Company paid investment banking fees of 13% of the gross proceeds of the offering. In addition, at completion of the offering, the placement agent will receive a five-year warrant to purchase a number of shares of common stock equal to 10% of the number of shares of common stock that may be issued upon the conversion of the notes. As of June 30, 2013, 113,920 of such warrant shares have been reflected as outstanding.

The net proceeds of the offering shall be used (i) to support the development and commercialization of MRI quality assurance software technologies; (ii) to support the development and commercialization of quality assurance software technologies for additional diagnostic modalities; and (iii) for general corporate purposes

The warrants and convertible debt instruments were issued, pursuant to the exemption from registration afforded by Section 4(2) of the Securities Act and Rule 506 of Regulation D thereunder. The Company relied on the following facts in making such exemption available: (i) the offer and sale of these securities was made to 54 accredited investors and therefore did not exceed the maximum purchaser limitation or violate the general solicitation rules; and (ii) all of the securities have the status of securities acquired in a transaction under Section 4(2) of the Securities Act and cannot be resold without registration or an exemption therefrom.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Nos.

4.1		Form of Tranche C Convertible Promissory Note, filed herewith.

4.2		Form of Tranche C Warrant, filed herewith.

4.3		Form of Tranche D Convertible Promissory Note, filed herewith.

4.4		Form of Tranche D Warrant, filed herewith.

31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

31.2		Certification of Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.1		Certifications of Principal Executive Officer and Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.
101.1		Financial Statements from the Quarterly Report on Form 10-Q of Vertical Health Solutions, Inc. for the quarter ended June 30, 2013, filed on August 14, 2013, formatted in XBRL (Extensible Business Report Language), (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Cash Flows and (iv) the Notes to the Consolidated Financial Statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VERTICAL HEALTH SOLUTIONS, INC.

Date: August 14, 2013	Vertical Health Solutions
	By: /s/ William T. Cavanaugh
	William T. Cavanaugh President and Chief Executive Officer

Date: August 14, 2013	Vertical Health Solutions
	By: /s/ James P. Marolt
	James P. Marolt Interim Chief Financial Officer

VERTICAL HEALTH SOLUTIONS INC 10-Q